Tuberculosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The trial takes place at primary care clinics in KwaZulu-Natal, Gauteng, and Eastern Cape provinces in South Africa that fall within selected hospital areas
- The clinics involved must have the support of provincial TB program managers, hospital leadership, and the clinic's nurse manager
- The clinics must see 10 or more patients diagnosed with drug-resistant TB per year and have access to laboratory testing, X-ray, and ECG (heart tracing) equipment
- Participants must be adults aged 18 or older, regardless of HIV status
- Participants must have a new diagnosis of rifampicin-resistant TB (a form of drug-resistant TB)
- Participants must be able to give informed consent in one of four languages: Zulu, Xhosa, Afrikaans, or English
Who may not be able to join:
- People whose condition requires a hospital stay rather than treatment at an outpatient clinic — for example, those with severe weakness, confusion, severe mental illness, very low blood pressure, severe difficulty breathing, or a temperature above 39°C
- People with a very low red blood cell count (haemoglobin below 8mg/dL) or signs of liver damage based on blood test results
- People whose heart electrical activity shows a prolonged interval (QTc above 470ms), confirmed by two or more ECG (heart tracing) tests
- People with a very fast heart rate (above 140 beats per minute) that remains after five minutes of rest
- People who are pregnant
- People who show signs that the TB infection has spread outside the lungs
- People already enrolled in another clinical trial that changes the treatment plan, its length, or how symptoms are managed
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jason Farley, PhD, MPH, ANP-BC, The Center for Infectious Disease and Nursing Innovation (CIDNI)
Phone: 4104091372
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
RR-TB treatment outcome; Severe Adverse Events as assessed by the Division of AIDS (DAIDS) AE grading table; Patient associated catastrophic costs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.